Increased incidence of psoriasis, possible disability, and negative impact on the quality of life of patients cause high importance of studying the issues of pathogenesis and treatment of psoriasis. It was found that changes in the microvasculature and rheological properties of blood hold a special place in formation of clinical manifestations of the disease. A significant role in the development of non-specific inflammatory changes in the walls of blood vessels, including those in the skin, belongs to increased activity of lipid peroxidation (LPO) processes along with decreased activity of antioxidant system performance. It was proved that activation of succinate oxidase oxidation by increasing the activity of succinate dehydrogenase and improving the penetration of exogenous and endogenous succinate into mitochondria, which can be achieved by including succinate-containing substances Remaxol and Reamberin to therapy, is the fastest way to correct these changes. Objective — this study was aimed at assessing the clinical efficacy of Remaxol and Reamberin in treatment of patients with progressive psoriasis. Material and methods. The study included 32 patients with progressive psoriasis accompanied by alcoholic liver toxicity, who underwent treatment at the hospital. Patients were divided into three groups. Group 1 patients received sodium thiosulfate; group 2 patients received Remaxol; group 3 patients received Reamberin. The severity of psoriasis was clinically assessed based on the analysis of dynamics of Psoriasis Area and Severity Index (PASI). In addition, the level of LPO products and the total antioxidant activity in the blood serum was assessed in all patients. Results. It was found that inclusion of Reamberin and Remaxol in treatment regimen of severe psoriasis resulted in increased efficacy of treatment as evidenced by reduced clinical manifestations of psoriasis (reduced PASI and DLQI) and significant improvement in liver tests. The most pronounced and statistically significant positive dynamics of clinical and laboratory parameters was observed in patients who received Remaxol.